Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease.
Yanai H, Adachi H, Hakoshima M, Katsuyama H.
Int J Mol Sci. 2021 Aug 26;22(17):9221. doi: 10.3390/ijms22179221.
Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation.
Johnson RJ, Bakris GL, Borghi C, Chonchol MB, Feldman D, Lanaspa MA, Merriman TR, Moe OW, Mount DB, Sanchez Lozada LG, Stahl E, Weiner DE, Chertow GM.
Am J Kidney Dis. 2018 Jun;71(6):851-865. doi: 10.1053/j.ajkd.2017.12.009. Epub 2018 Feb 27.
PMID:29496260
The SGLT2 inhibitor dapagliflozin ameliorates renal fibrosis in hyperuricemic nephropathy.
Hu H, Li W, Hao Y, Peng Z, Zou Z, Wei J, Zhou Y, Liang W, Cao Y.
Cell Rep Med. 2024 Aug 20;5(8):101690. doi: 10.1016/j.xcrm.2024.101690.
PMID:39168099
Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis.
Kimura Y, Tsukui D, Kono H.
Int J Mol Sci. 2021 Nov 17;22(22):12394. doi: 10.3390/ijms222212394.